You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
柳藥股份(603368.SH):2019年淨利預增28.74%-38.21%
格隆匯 01-10 17:12

格隆匯1月10日丨柳藥股份(603368.SH)披露2019年年度業績預增公告,公司預計2019年度實現歸屬於上市公司股東的淨利潤為6.8億元-7.3億元,同比增加28.74%-38.21%;公司預計2019年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤為6.663億元-7.163億元,同比增加26.07%-35.53%。

業績預增的主要原因:

(一)主營業務影響

報告期內,公司主營業務醫藥批發和零售保持良好增長。公司主營業務增長的主要原因是:在醫改政策推動下,行業配送集中度提升,公司通過供應鏈增值服務和分銷網絡的拓展,保持醫院銷售業務的穩健增長;在零售業務方面,公司零售藥店規模持續擴大,DTP藥店業務大幅增長,共同推動零售業務的快速增長。同時公司加快創新藥品、醫療器械和中藥飲片品種引進和銷售,品種結構不斷優化,醫藥工業板塊業務持續擴大,逐步形成新的利潤增長點。

(二)非經營性損益的影響

報告期內,公司收到的政府補助有所增加。

(三)會計處理的影響

與 2018年相比,廣西萬通製藥有限公司、廣西新友和古城大藥房有限責任公司2019年全年納入公司合併報表範圍,增厚公司收入和利潤。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account